Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Houston, Texas 77030


This is a companion protocol to MD Anderson Cancer Center study 2010-0085 (Sequential Therapy in Advanced Renal Cell Carcinoma Therapy: The "START" Trial). The goal of this clinical research study is to learn if dynamic contrast enhanced computed tomography (DCE-CT) scans can help researchers learn if the study drug received as part of study 2010-0085 (either everolimus, bevacizumab, or pazopanib) is working.

Study summary:

To perform a DCE-CT scan, a small amount of a special dye (called "CT contrast medium") is injected by vein into the body. Several CT images are then taken over a few minutes to learn how much dye spreads outside of the tumor. This can show how much blood flows to and from the tumor. By performing DCE-CT scans after several weeks on treatment, researchers may learn if changes in blood flow may be a sign that the treatment is working. Study Procedures: If you are found to be eligible to take part in this study, you will have a DCE-CT scan to check the status of the disease at the following times: - Within about 4 weeks before you begin treatment on study 2010-0085. - Eight (8) weeks after starting treatment on study 2010-0085. Before each of the DCE-CT scans are performed, blood (about 1 tablespoon) will be drawn to check your kidney function. If your doctor thinks it is needed, you will also have a standard-of-care CT scan at these timepoints to check the status of the disease. Length of Study: Your participation in this study will be over after the scan(s) 8 weeks after starting treatment on study 2010-0085. You will be taken off of this study if you leave the 2010-0085 study early. This is an investigational study. The DCE-CT scan is commercially available. Using DCE-CT scans to check the status of kidney cancer is investigational. Up to 120 patients will take part in this study. All will be enrolled at MD Anderson.


Inclusion Criteria: 1. Patient must be enrolled or being considered for enrollment on protocol 2010-0085. 2. Patients must have metastatic renal cell carcinoma (RCC). 3. Age >/= 18 years. 4. Subjects must have adequate renal function as defined by serum creatinine < 1.5x upper limit of normal. Exclusion Criteria: 1. Radiotherapy: Subjects may not have received prior radiotherapy to the index lesion within 4 weeks 2. Female subjects who are pregnant or lactating. 3. Female subjects of childbearing potential (unless they have a negative serum or urine pregnancy test within 3 days prior to start of study treatment). 4. Allergy to CT contrast media requiring the administration of steroid prophylaxis.

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Th

Official Title:

Dynamic Contrast Enhancement Computed Tomography for Evaluating Tumor Perfusion in Patients With Metastatic Renal Cell Carcinoma Receiving Targeted Therapies: Companion to Protocol 2010-0085

Overall Status:

Active, not recruiting

Study Phase:

Phase 3



Minimum Age:

18 Years

Maximum Age:


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

M.D. Anderson Cancer Center

Oversight Authority:

United States: Food and Drug Administration

Reasons Why Stopped:

Study Type:


Study Design:

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Chaan Ng, MD
Principal Investigator
M.D. Anderson Cancer Center

Study Dates

Start Date:January 2011
Completion Date:January 2021
Completion Type:Anticipated
Primary Completion Date:January 2020
Primary Completion Type:Anticipated
Verification Date:May 2019
Last Changed Date:May 9, 2019
First Received Date:October 18, 2010

Study Outcomes

Outcome Type:Primary Outcome
Measure:Tumor Blood Flow (BF) Reduction
Time Frame:From 4 weeks prior to first dose to 8 weeks post treatment
Safety Issues:False
Description:Changes in perfusion parameters assessed at first re-staging (approximately 8 weeks) and shortly after initiating therapy (2 - 7 days), for three different therapies using organ-directed DCE-CT tumor assessments. Tumor BF of index lesions computed using c
Outcome Type:Secondary Outcome
Measure:Progression Free Survival (PFS)
Time Frame:3 years
Safety Issues:False
Description:PFS is calculated from the start of the study until disease progression.

Study Interventions

Intervention Type:Procedure
Name:Perfusion CT scan
Description:DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
Arm Name:DCE-CT Scans

Study Arms

Study Arm Type:Experimental
Arm Name:DCE-CT Scans
Description:DCE-CT = Dynamic contrast enhanced CT - DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.

Study Agencies

Agency Class:Other
Agency Type:Lead Sponsor
Agency Name:M.D. Anderson Cancer Center

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.